UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   May 8, 2008

NASTECH PHARMACEUTICAL COMPANY INC.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-13789 11-2658569
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
3830 Monte Villa Parkway, Bothell, Washington   98021
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   425-908-3600

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On May 8, 2008, Nastech Pharmaceutical Company Inc. (the "Registrant") reported its financial results for the quarter ended March 31, 2008. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information contained herein and in the accompanying exhibit is being furnished pursuant to "Item 2.02 Results of Operations and Financial Condition." The information contained herein and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.





Item 9.01 Financial Statements and Exhibits.

(c) Exhibit.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    NASTECH PHARMACEUTICAL COMPANY INC.
          
May 8, 2008   By:   Bruce R. York
       
        Name: Bruce R. York
        Title: Chief Financial Officer

Exhibit Index


     
Exhibit No.   Description
 
99.1
  Press Release of Nastech Pharmaceutical Company Inc. dated May 8, 2008.
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Nastech Pharmaceutical Company (MM) Charts.
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Nastech Pharmaceutical Company (MM) Charts.